Therapeutic potential of endothelin receptor antagonists in diabetes

被引：11
|
作者：
Chakrabarti, S [1 ]
Cukiernik, M [1 ]
Mukherjee, S [1 ]
Chen, SL [1 ]
机构：
[1] Univ Western Ontario, Dept Pathol, London, ON, Canada
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2000年 / 9卷 / 12期
关键词：
cardiomyopathy; diabetic complications; endothelins; endothelin antagonism; nephropathy; neuropathy; retinopathy;
D O I：
10.1517/13543784.9.12.2873
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Endothelins (ETs) are widely distributed in the body and perform several vascular and non-vascular functions. Experimental evidence indicates that abnormalities of the ET system occur in several organs affected in chronic diabetic complications. Furthermore, ET antagonists were found to prevent structural and functional changes in the target organs of chronic diabetic complications in animal models. Abnormalities of plasma ET levels have also been demonstrated in human diabetes. This review discusses the role of ET in the pathogenesis of chronic diabetic complications. The current experimental evidence suggests that ET antagonism may potentially represent an adjuvant therapeutic tool in the treatment of chronic diabetic complications.
引用
收藏
页码：2873 / 2888
页数：16
相关论文
共 50 条
  • [1] Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders
    Spieker L.E.
    Noll G.
    Lüscher T.F.
    American Journal of Cardiovascular Drugs, 2001, 1 (4) : 293 - 303
  • [2] THERAPEUTIC POTENTIAL OF ENDOTHELIN RECEPTOR ANTAGONISTS IN EXPERIMENTAL STROKE
    PATEL, TR
    GALBRAITH, SL
    MCAULEY, MA
    DOHERTY, AM
    GRAHAM, DI
    MCCULLOCH, J
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 : S412 - S415
  • [3] Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease
    Patel, TR
    CNS DRUGS, 1996, 5 (04) : 293 - 310
  • [4] Development of endothelin receptor antagonists as potential therapeutic agents
    Ergul, A
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2003, 13 (01) : 33 - 44
  • [5] The therapeutic potential of endothelin receptor antagonists in cardiovascular disease
    Barton M.
    Kiowski W.
    Current Hypertension Reports, 2001, 3 (4) : 322 - 330
  • [6] Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents
    Ergul, A
    PHARMACOTHERAPY, 2002, 22 (01): : 54 - 65
  • [7] Endothelin receptors: Receptor classification, novel receptor antagonists, and potential therapeutic targets
    Ohlstein, EH
    Elliott, JD
    Feuerstein, GZ
    Ruffolo, RR
    MEDICINAL RESEARCH REVIEWS, 1996, 16 (04) : 365 - 390
  • [8] The renoprotective potential of endothelin receptor antagonists
    Benigni, A
    Remuzzi, G
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1997, 7 (02) : 139 - 149
  • [9] The renoprotective potential of endothelin receptor antagonists
    Knoll, T
    Schaub, M
    Birck, R
    Braun, C
    Juenemann, KP
    Rohmeiss, P
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (05) : 1041 - 1052
  • [10] Therapeutic potential of endothelin receptor antagonists and nitric oxide donors in pulmonary hypertension
    Tilton, RG
    Brock, TA
    Dixon, RAF
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (07) : 1291 - 1308
12345